查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1750632

全球鐮狀細胞性貧血快速 POC 檢測市場規模、佔有率和趨勢分析報告：按類型、技術、應用、機構類型、最終用途、配銷通路、地區和細分市場預測 2025-2030 年

Rapid Point-of-Care Testing for Sickle Cell Anemia Market Size, Share & Trends Analysis Report By Type, By Technology, By Age Group, By Distribution Channel, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 320 Pages | 商品交期: 2-10個工作天內

價格

鐮狀細胞性貧血快速 POC 檢測市場成長與趨勢：

根據 Grand View Research, Inc. 的新報告，全球鐮狀細胞性貧血快速 POC 檢測市場規模預計到 2030 年將達到 5.2283 億美元，2025 年至 2030 年期間的複合年成長率為 9.7%。

鐮狀細胞疾病 (SCD) 是一種遺傳性血液疾病，會導致紅血球形態異常，並可能因鐮狀細胞阻塞血流而引發劇烈疼痛、貧血和器官損傷。根據《血液學與相關科學期刊》(JHAS) 報導，印度是世界上鐮狀B珠蛋白等位基因頻率最高的國家之一。早期準確檢測SCD對於有效的管理和治療至關重要。傳統的診斷方法通常需要專業的醫療機構和設備齊全的實驗室，而這些在資源匱乏的地區可能無法實現。鑑於這些挑戰，快速即時檢測 (POC) 已成為一種更有效率、更便捷的SCD診斷方法。

POC 檢測具有許多優勢，包括快速出結果、易於使用以及適用於分散式醫療環境。這些特點在 SCD 高發生地區尤其有利，因為早期診斷和早期療育將顯著改善患者的預後。透過及時檢測，POC 檢測可以降低未確診 SCD 導致嚴重併發症和死亡的風險，有助於更好地管理疾病。此外，POC 檢測在新生兒篩檢計畫中發揮重要作用，有助於在出生時識別受影響的嬰兒並立即啟動治療。側流免疫檢測(LFIA) 的最新進展顯著提高了 SCD 的診斷率，尤其是在資源匱乏的地區。其中一項創新進展是多重對偶基因特異性特異性重組聚合酵素(RPA) 檢測。此外，將光學奈米粒子納入 LFIA 平台提高了這些檢測的敏感度和特異性，使其成為 SCD 和其他疾病的有力診斷工具。

另一項值得注意的創新是 E-junction 側流免疫檢測，專為在中低收入國家 (LMIC) 進行大規模 SCD篩檢設計。這款價格低廉、易於使用的 POC 設備只需一滴全血即可診斷健康個體、SCD 患者和攜帶者。它的成本效益和可靠性使其成為傳統診斷方法有限的地區的理想選擇，有助於解決因延遲診斷而導致的高死亡率。同樣，Sickle SCAN POC 設備在檢測血紅蛋白變體 HbA、HbS 和 HbC 方面表現出優異的靈敏度和特異性。該測試在液體和乾血斑 (DBS) 中均有效，即使在胎兒血紅蛋白 (HbF) 含量高的檢體中也是如此，這使其成為資源受限地區廣泛篩檢的理想選擇。 HemoTypeSC 測試是另一種有前景的早期 SCD 檢測方法，它也具有高度的敏感度和特異性，使其特別適用於大規模篩檢計畫。通常由非政府組織主導的流動醫療團隊和社區推廣計畫對於在資源匱乏的地區提供快速即時檢測也至關重要。這些努力不僅改善了診斷服務的可近性，也提高了人們對SCD和早期療育重要性的認知。此外，非政府組織與私人公司之間的夥伴關係也有助於津貼診斷檢測，使其更便宜，並在各種醫療環境中推廣。

諸如國家鐮狀細胞性貧血消除行動 (NSCAEM) 等有針對性的舉措旨在透過全民篩檢、意識提升宣傳活動和改善疾病管理，到 2047 年消除鐮狀性貧血這一公共衛生問題。該行動計劃篩檢約 7000 萬名 0-40 歲人群，初期重點關注古吉拉突邦和馬哈拉斯特拉邦等患病率較高的邦，同時與國家衛生使命 (NHM) 合作，以高效利用資源。

鐮狀細胞性貧血快速 POC 檢測市場報告重點

  • 按類型分類，側流免疫測量法憑藉其價格實惠、操作簡便、結果快速準確等優勢，在2024年佔據51.66%的市場佔有率，佔據市場領先地位。側流免疫測定法能夠檢測多種血紅蛋白變異體，適用於資源匱乏的環境，因此在全球診斷市場中日益普及。
  • 從技術面來看，血紅素電泳技術憑藉其在血紅蛋白病檢測方面的高準確性，在2024年以48.99%的市佔率領先市場。作為一種可靠的診斷方法，它能夠準確識別鐮狀細胞疾病和其他血紅蛋白變異體，這對於早期療育和疾病管理至關重要。
  • 從應用角度來看，新生兒篩檢（<12個月）預計將在2024年引領市場，並有望在預測期內實現最快的複合年成長率，這得益於人們對早期診斷的認知和重視程度的不斷提高。透過POC檢測進行早期發現，可以及時治療，減少併發症，並改善患兒的長期預後。
  • 在國家措施和技術進步的推動下，政府實驗室領域正在經歷顯著成長。印度醫學研究理事會 (ICMR) 已核准現有的鐮狀細胞疾病篩檢即時篩檢(POC)，並鼓勵各邦實施一級或二級篩檢方法。
  • 鐮狀細胞病患疾病率不斷上升和及時診斷需求的推動，醫院和診所終端用途領域正在經歷顯著成長。
  • 從分銷管道來看，由於對便捷高效的診斷解決方案的需求不斷成長，B2B 領域正在經歷顯著成長。各公司正在建立策略夥伴關係關係，以擴大產品供應並拓展更廣闊的市場。
  • 在對可訪問和高效的診斷解決方案的需求不斷成長的推動下，鐮狀細胞性貧血快速 POC 檢測行業由北美主導，2024 年的收入佔有率為 43.97%。這種擴張歸因於慢性病盛行率上升、診斷技術的進步以及政府和私人機構資金增加等因素。
  • BioMedomics 和 Silver Lake Research 等主要企業憑藉 Sickle SCAN 和 HemoTypeSC 等高靈敏度和高特異性檢測引領市場。隨著這些公司提升診斷能力、縮短週轉時間並協助鐮狀細胞疾病的早期療育，市場有望成長。

目錄

第1章調查方法與範圍

第2章執行摘要

鐮狀細胞性貧血快速 POC 檢測市場變數、趨勢與範圍

  • 市場展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 鐮狀細胞性貧血快速 POC 檢測市場分析工具
    • 產業分析：波特五力分析
    • PESTEL分析

鐮狀細胞性貧血快速 POC 檢測市場：類型估計和趨勢分析

  • 2024 年及 2030 年各類型市場佔有率
  • 細分儀表板
  • 全球鐮狀細胞性貧血快速 POC 檢測市場：按類型展望
  • 市場規模、預測與趨勢分析（2018-2030年）
    • 側流免疫測量
    • 紙本快速診斷
    • 其他

鐮狀細胞性貧血快速 POC 檢測市場：技術評估與趨勢分析

  • 2024 年及 2030 年技術市場佔有率
  • 細分儀表板
  • 全球鐮狀細胞性貧血快速即時檢測市場：技術展望
  • 市場規模、預測與趨勢分析（2018-2030年）
    • 血紅素電泳
    • 聚合酵素鏈鎖反應（PCR）
    • 等溫擴增試驗
    • 其他

第6章鐮狀細胞性貧血快速POC檢測市場：應用評估與趨勢分析

  • 2024 年及 2030 年各應用領域的市場佔有率
  • 細分儀表板
  • 全球鐮狀細胞性貧血快速即時檢測市場：應用前景
  • 市場規模、預測與趨勢分析（2018-2030年）
    • 新生兒篩檢（<12個月）
    • 成人篩檢（25-60歲）
    • 其他年齡層（1-25歲及60歲以上）

鐮狀細胞性貧血快速 POC 檢測市場：機構類型估計與趨勢分析

  • 2024 年及 2030 年機構類型市場佔有率
  • 細分儀表板
  • 全球鐮狀細胞性貧血快速 POC 檢測市場：依機構類型展望
  • 市場規模、預測與趨勢分析（2018-2030年）
    • 政府實驗室
    • 私人實驗室
    • 企業實驗室
    • PPP（官民合作關係）

鐮狀細胞性貧血快速 POC 檢測市場：最終用途估計與趨勢分析

  • 2024 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • 全球鐮狀細胞性貧血快速即時檢測市場：最終用途展望
  • 市場規模、預測與趨勢分析（2018-2030年）
    • 研究所
    • 醫院和診所
    • 診斷實驗室
    • 居家照護環境
    • 其他

鐮狀細胞性貧血快速 POC 檢測市場：通路評估與趨勢分析

  • 2024年及2030年分銷通路市場佔有率
  • 細分儀表板
  • 全球鐮狀細胞性貧血快速 POC 檢測市場：通路展望
  • 市場規模、預測與趨勢分析（2018-2030年）
    • B2B（企業對企業）
    • B2C（企業對消費者）

鐮狀細胞性貧血快速 POC 檢測市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 市場規模、預測與趨勢分析（2018-2030年）
  • 北美洲
    • 北美：SWOT分析
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲：SWOT分析
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 亞太地區：SWOT分析
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲：SWOT分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第11章競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • 主要客戶
    • 主要企業市場佔有率分析（2024年）
    • BIOMEDOMICS INC.
    • Silver Lake Research Corporation
    • Bio-Rad Laboratories, Inc.
    • Trivitron Healthcare
    • Hemex Health
    • Sysmex Corporation
    • EKF Diagnostics Holdings plc.
    • HemoCue America（Danaher）
    • Rapid Point-of-Care Testing for Sickle Cell Anemias Inc
Product Code: GVR-4-68040-567-0

Rapid Point-of-Care Testing for Sickle Cell Anemia Market Growth & Trends:

The global rapid point-of-care testing for sickle cell anemia market size is expected to reach USD 522.83 million by 2030, registering a CAGR of 9.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Sickle Cell Disease (SCD) is a genetic blood disorder that results in the production of abnormally shaped red blood cells, leading to severe pain, anemia, and potential organ damage due to these sickle-shaped cells obstructing blood flow. India, according to the Journal of Hematology and Allied Science (JHAS), has one of the highest frequencies of the sickle B-globin allele. Early and accurate detection of SCD is critical for effective management and treatment. Traditional diagnostic methods often require specialized healthcare facilities and well-equipped laboratories, which may be inaccessible in resource-limited areas. This challenge has driven the growth of rapid point-of-care (POC) testing technologies, offering a more efficient and accessible alternative for diagnosing SCD.

POC testing offers several benefits, including fast results, ease of use, and suitability for decentralized healthcare settings. These features are particularly advantageous in regions with high SCD prevalence, where early diagnosis and intervention can substantially improve patient outcomes. By enabling timely detection, POC testing helps in better disease management, reducing the risk of severe complications and mortality associated with undiagnosed SCD. Furthermore, POC tests play a key role in newborn screening programs, helping to identify affected infants at birth and begin treatment immediately. Recent advancements in lateral flow immunoassays (LFIA) have significantly improved the diagnosis of SCD, particularly in low-resource settings. One innovative development is the multiplexed, allele-specific recombinase polymerase amplification (RPA) assay, which uses a lateral flow readout to detect multiple mutations in the B-globin gene, the primary cause of SCD, offering an efficient and accurate rapid diagnostic method. Additionally, integrating optical nanoparticles into LFIA platforms has enhanced the sensitivity and specificity of these tests, making them powerful diagnostic tools for SCD and other diseases.

Another notable innovation is the E-junction lateral flow immunoassay, designed for large-scale SCD screening in low- and middle-income countries (LMICs). This affordable, user-friendly POC device can diagnose healthy individuals, SCD patients, and carriers using just a single drop of whole blood. Its cost-effectiveness and reliability make it ideal for areas with limited access to traditional diagnostic methods, helping address the high mortality rates caused by delayed diagnoses. Similarly, the Sickle SCAN POC device demonstrates impressive sensitivity and specificity in detecting hemoglobin variants HbA, HbS, and HbC. It works effectively with both liquid blood and dried blood spots (DBS), even in samples containing high levels of fetal hemoglobin (HbF), making it an excellent choice for widespread screening in resource-constrained regions. The HemoTypeSC test, another promising tool for early SCD detection, is also highly sensitive and specific, particularly useful for large-scale screening programs. Mobile health units and community outreach programs, often led by NGOs, are also integral to providing rapid POC testing in resource-poor settings. These efforts not only enhance access to diagnostic services but also raise awareness about SCD and the importance of early intervention. Moreover, partnerships between NGOs and private companies have helped subsidize diagnostic tests, making them more affordable and scalable across various healthcare environments.

Targeted initiatives, such as the National Sickle Cell Anaemia Elimination Mission (NSCAEM), aim to eradicate sickle cell anemia as a public health issue by 2047 through universal screening, awareness campaigns, and improved disease management. The mission aims to screen about 70 million people aged 0-40, initially focusing on high-prevalence states like Gujarat and Maharashtra, while collaborating with the National Health Mission (NHM) for effective resource utilization.

Rapid Point-of-Care Testing for Sickle Cell Anemia Market Report Highlights:

  • Based on type, the lateral flow immunoassay segment led the market in 2024 with a 51.66% share, due to its affordability, ease of use, and fast, accurate results. LFIA's ability to detect multiple hemoglobin variants and its suitability for low-resource settings contribute to its increasing adoption in global diagnostics.
  • Based on technology, the hemoglobin electrophoresis segment led the market in 2024 with a 48.99% share, driven by its high accuracy in detecting hemoglobinopathies. As a reliable diagnostic method, it allows for precise identification of sickle cell disease and other hemoglobin variants, making it crucial for early intervention and disease management.
  • Based on age group, the newborn screening (12 months and below) segment led the market in 2024 and is expected to witness the fastest CAGR during the forecast period, due to growing awareness and the importance of early diagnosis. Early detection through POC testing allows for prompt treatment, reducing complications and improving long-term outcomes for affected infants.
  • The government laboratories sector type segment is experiencing significant growth, driven by national initiatives and technological advancements. The Indian Council of Medical Research (ICMR) has endorsed existing POC tests for sickle cell disease screening, encouraging states to implement one or two-level screening approaches.
  • The hospitals & clinics end use segment is experiencing substantial growth, driven by the increasing prevalence of sickle cell disease and the demand for timely diagnostics.
  • Based on distribution channel, the Business-to-Business (B2B) segment is experiencing significant growth, driven by increasing demand for accessible and efficient diagnostic solutions. Companies are forming strategic partnerships to expand their product offerings and reach broader markets.
  • North America dominated the global Rapid point-of-care testing for sickle cell anemia industry with a revenue share of 43.97% in 2024, driven by increasing demand for accessible and efficient diagnostic solutions. This expansion is attributed to factors such as the rising prevalence of chronic diseases, advancements in diagnostic technologies, and increased funding from government and private institutions.
  • Companies like BioMedomics and Silver Lake Research are leading the way with highly sensitive and specific tests, such as Sickle SCAN and HemoTypeSC, respectively, while others are leveraging global distribution networks to reach underserved populations. The market is poised for growth as these players work to enhance diagnostic capabilities, reduce turnaround times, and support early intervention efforts for sickle cell disease

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Technology
    • 1.2.3. Age group
    • 1.2.4. Sector Type
    • 1.2.5. End Use
    • 1.2.6. Distribution Channel
    • 1.2.7. Regional scope
    • 1.2.8. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type Outlook
    • 2.2.2. Technology Outlook
    • 2.2.3. Age Group Outlook
    • 2.2.4. Sector Type
    • 2.2.5. End Use Outlook
    • 2.2.6. Distribution Channel
    • 2.2.7. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Rapid Point-of-Care Testing for Sickle Cell Anemia Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising demand for personalized medicine and genomic research
      • 3.2.1.2. Growing prevalence of sickle cell disease (SCD)
      • 3.2.1.3. Advancements in diagnostic technology
      • 3.2.1.4. Government and NGO initiatives for early point-of-care (POC) screening
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Limited accessibility to advanced technologies
  • 3.3. Rapid Point-of-Care Testing for Sickle Cell Anemia Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Lateral Flow Immunoassay
      • 4.4.1.1. Lateral Flow Immunoassay market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Paper-Based Rapid Diagnostics
      • 4.4.2.1. Paper-Based Rapid Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Others
      • 4.4.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hemoglobin Electrophoresis
      • 5.4.1.1. Hemoglobin Electrophoresis market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Polymerase Chain Reaction (PCR)
      • 5.4.2.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Isothermal Amplification Assays
      • 5.4.3.1. Isothermal Amplification Assays market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Others
      • 5.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Newborn Screening (12 months and below)
      • 6.4.1.1. Newborn Screening (12 months and below) market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Adult Screening (25 to 60 years)
      • 6.4.2.1. Adult Screening (25 to 60 years) market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Other Age Groups (1 to 25 & Above 60 years)
      • 6.4.3.1. Other Age Groups (1 to 25 & Above 60 years) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Sector Type Estimates & Trend Analysis

  • 7.1. Sector Type Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Sector Type Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Government Labs
      • 7.4.1.1. Government Labs market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Private Labs
      • 7.4.2.1. Private Labs market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Corporate Labs
      • 7.4.3.1. Corporate Labs market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. PPP (Public-Private-Partnerships)
      • 7.4.4.1. PPP (Public-Private-Partnerships) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: End Use Estimates & Trend Analysis

  • 8.1. End Use Market Share, 2024 & 2030
  • 8.2. Segment Dashboard
  • 8.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by End Use Outlook
  • 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 8.4.1. Research Institutions
      • 8.4.1.1. Research Institutions market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Hospitals & Clinics
      • 8.4.2.1. Hospitals & Clinics market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. Diagnostic Laboratories
      • 8.4.3.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Homecare Settings
      • 8.4.4.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Others
      • 8.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Distribution Channel Estimates & Trend Analysis

  • 9.1. Distribution Channel Market Share, 2024 & 2030
  • 9.2. Segment Dashboard
  • 9.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Distribution Channel Outlook
  • 9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 9.4.1. B2B (Business-to-Business)
      • 9.4.1.1. B2B (Business-to-Business) market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.2. B2C (Business-to-Consumer)
      • 9.4.2.1. B2C (Business-to-Consumer) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Share Analysis, 2024 & 2030
  • 10.2. Regional Market Dashboard
  • 10.3. Global Regional Market Snapshot
  • 10.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 10.5. North America
    • 10.5.1. North America: SWOT Analysis
    • 10.5.2. U.S.
      • 10.5.2.1. Key country dynamics
      • 10.5.2.2. Regulatory framework
      • 10.5.2.3. Competitive scenario
      • 10.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.3. Canada
      • 10.5.3.1. Key country dynamics
      • 10.5.3.2. Regulatory framework
      • 10.5.3.3. Competitive scenario
      • 10.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.4. Mexico
      • 10.5.4.1. Key country dynamics
      • 10.5.4.2. Regulatory framework
      • 10.5.4.3. Competitive scenario
      • 10.5.4.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6. Europe
    • 10.6.1. Europe: SWOT Analysis
    • 10.6.2. UK
      • 10.6.2.1. Key country dynamics
      • 10.6.2.2. Regulatory framework
      • 10.6.2.3. Competitive scenario
      • 10.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.3. Germany
      • 10.6.3.1. Key country dynamics
      • 10.6.3.2. Regulatory framework
      • 10.6.3.3. Competitive scenario
      • 10.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.4. France
      • 10.6.4.1. Key country dynamics
      • 10.6.4.2. Regulatory framework
      • 10.6.4.3. Competitive scenario
      • 10.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.5. Italy
      • 10.6.5.1. Key country dynamics
      • 10.6.5.2. Regulatory framework
      • 10.6.5.3. Competitive scenario
      • 10.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.6. Spain
      • 10.6.6.1. Key country dynamics
      • 10.6.6.2. Regulatory framework
      • 10.6.6.3. Competitive scenario
      • 10.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.7. Norway
      • 10.6.7.1. Key country dynamics
      • 10.6.7.2. Regulatory framework
      • 10.6.7.3. Competitive scenario
      • 10.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.8. Sweden
      • 10.6.8.1. Key country dynamics
      • 10.6.8.2. Regulatory framework
      • 10.6.8.3. Competitive scenario
      • 10.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.9. Denmark
      • 10.6.9.1. Key country dynamics
      • 10.6.9.2. Regulatory framework
      • 10.6.9.3. Competitive scenario
      • 10.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7. Asia Pacific
    • 10.7.1. Asia Pacific: SWOT Analysis
    • 10.7.2. Japan
      • 10.7.2.1. Key country dynamics
      • 10.7.2.2. Regulatory framework
      • 10.7.2.3. Competitive scenario
      • 10.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.3. China
      • 10.7.3.1. Key country dynamics
      • 10.7.3.2. Regulatory framework
      • 10.7.3.3. Competitive scenario
      • 10.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.4. India
      • 10.7.4.1. Key country dynamics
      • 10.7.4.2. Regulatory framework
      • 10.7.4.3. Competitive scenario
      • 10.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.5. Australia
      • 10.7.5.1. Key country dynamics
      • 10.7.5.2. Regulatory framework
      • 10.7.5.3. Competitive scenario
      • 10.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.6. South Korea
      • 10.7.6.1. Key country dynamics
      • 10.7.6.2. Regulatory framework
      • 10.7.6.3. Competitive scenario
      • 10.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.7. Thailand
      • 10.7.7.1. Key country dynamics
      • 10.7.7.2. Regulatory framework
      • 10.7.7.3. Competitive scenario
      • 10.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.8. Latin America
    • 10.8.1. Latin America: SWOT Analysis
    • 10.8.2. Brazil
      • 10.8.2.1. Key country dynamics
      • 10.8.2.2. Regulatory framework
      • 10.8.2.3. Competitive scenario
      • 10.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.8.3. Argentina
      • 10.8.3.1. Key country dynamics
      • 10.8.3.2. Regulatory framework
      • 10.8.3.3. Competitive scenario
      • 10.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.9. MEA
    • 10.9.1. MEA: SWOT Analysis
    • 10.9.2. South Africa
      • 10.9.2.1. Key country dynamics
      • 10.9.2.2. Regulatory framework
      • 10.9.2.3. Competitive scenario
      • 10.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.9.3. Saudi Arabia
      • 10.9.3.1. Key country dynamics
      • 10.9.3.2. Regulatory framework
      • 10.9.3.3. Competitive scenario
      • 10.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.9.4. UAE
      • 10.9.4.1. Key country dynamics
      • 10.9.4.2. Regulatory framework
      • 10.9.4.3. Competitive scenario
      • 10.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.9.5. Kuwait
      • 10.9.5.1. Key country dynamics
      • 10.9.5.2. Regulatory framework
      • 10.9.5.3. Competitive scenario
      • 10.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 11.2. Company/Competition Categorization
  • 11.3. Vendor Landscape
    • 11.3.1. List of key distributors and channel partners
    • 11.3.2. Key customers
    • 11.3.3. Key company market share analysis, 2024
    • 11.3.4. BIOMEDOMICS INC.
      • 11.3.4.1. Company overview
      • 11.3.4.2. Financial performance
      • 11.3.4.3. Services benchmarking
      • 11.3.4.4. Strategic initiatives
    • 11.3.5. Silver Lake Research Corporation
      • 11.3.5.1. Company overview
      • 11.3.5.2. Financial performance
      • 11.3.5.3. Services benchmarking
      • 11.3.5.4. Strategic initiatives
    • 11.3.6. Bio-Rad Laboratories, Inc.
      • 11.3.6.1. Company overview
      • 11.3.6.2. Financial performance
      • 11.3.6.3. Services benchmarking
      • 11.3.6.4. Strategic initiatives
    • 11.3.7. Trivitron Healthcare
      • 11.3.7.1. Company overview
      • 11.3.7.2. Financial performance
      • 11.3.7.3. Services benchmarking
      • 11.3.7.4. Strategic initiatives
    • 11.3.8. Hemex Health
      • 11.3.8.1. Company overview
      • 11.3.8.2. Financial performance
      • 11.3.8.3. Services benchmarking
      • 11.3.8.4. Strategic initiatives
    • 11.3.9. Sysmex Corporation
      • 11.3.9.1. Company overview
      • 11.3.9.2. Financial performance
      • 11.3.9.3. Services benchmarking
      • 11.3.9.4. Strategic initiatives
    • 11.3.10. EKF Diagnostics Holdings plc.
      • 11.3.10.1. Company overview
      • 11.3.10.2. Financial performance
      • 11.3.10.3. Services benchmarking
      • 11.3.10.4. Strategic initiatives
    • 11.3.11. HemoCue America (Danaher)
      • 11.3.11.1. Company overview
      • 11.3.11.2. Financial performance
      • 11.3.11.3. Services benchmarking
      • 11.3.11.4. Strategic initiatives
    • 11.3.12. Rapid Point-of-Care Testing for Sickle Cell Anemias Inc
      • 11.3.12.1. Company overview
      • 11.3.12.2. Financial performance
      • 11.3.12.3. Services benchmarking
      • 11.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 List of Secondary Sources
  • Table 3 Regulatory Framework
  • Table 4 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 6 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 7 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 USD Million
  • Table 8 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 9 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 10 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
  • Table 12 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 13 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 14 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 15 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 16 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 17 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 19 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 20 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 21 U.S Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 22 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 23 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 25 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 26 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 27 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 28 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 29 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 31 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 32 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 33 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 34 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 35 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
  • Table 37 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 38 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 39 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 40 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 41 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 42 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 44 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 45 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 46 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 47 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 48 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 50 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 51 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 52 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 53 Germany America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 54 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 56 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 57 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 58 France Rapid Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 59 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 60 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 62 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 63 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 64 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 65 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 66 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 68 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 69 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 70 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 71 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 72 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
  • Table 74 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 75 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 76 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 77 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 78 Asia-Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 79 Asia-Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 81 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 82 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 83 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 84 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 85 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 87 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 88 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 89 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 90 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 91 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 93 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 94 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 95 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 96 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 97 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 98 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 99 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 100 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 101 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 102 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 103 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 104 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 105 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 106 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 107 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 108 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 109 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 110 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
  • Table 111 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 112 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 113 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 114 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 115 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 116 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 117 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 118 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 119 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 120 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 121 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 122 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 123 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 124 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 125 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 126 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 127 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 128 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 129 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
  • Table 130 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 131 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 132 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 133 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 134 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 135 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 136 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 137 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 138 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 139 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 140 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 141 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 142 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 143 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 144 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 145 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 146 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 147 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million) million
  • Table 148 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 149 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 150 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 151 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 152 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 153 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Rapid Point-of-Care Testing for Sickle Cell Anemia: market outlook
  • Fig. 14 Rapid Point-of-Care Testing for Sickle Cell Anemia competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook.
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Rapid Point-of-Care Testing for Sickle Cell Anemia driver impact
  • Fig. 20 Rapid Point-of-Care Testing for Sickle Cell Anemia restraint impact
  • Fig. 21 Rapid Point-of-Care Testing for Sickle Cell Anemia strategic initiatives analysis
  • Fig. 22 Rapid Point-of-Care Testing for Sickle Cell Anemia: Type movement analysis
  • Fig. 23 Rapid Point-of-Care Testing for Sickle Cell Anemia: Type outlook and key takeaways
  • Fig. 24 Lateral Flow Immunoassay market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Paper-Based Rapid Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Rapid Point-of-Care Testing for Sickle Cell Anemia: Technology movement analysis
  • Fig. 28 Rapid Point-of-Care Testing for Sickle Cell Anemia: Technology outlook and key takeaways
  • Fig. 29 Hemoglobin Electrophoresis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Polymerase Chain Reaction (PCR) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Isothermal Amplification Assays market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Rapid Point-of-Care Testing for Sickle Cell Anemia: Age Group movement analysis
  • Fig. 34 Rapid Point-of-Care Testing for Sickle Cell Anemia: Age Group outlook and key takeaways
  • Fig. 35 Newborn Screening (12 months and below) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Adult Screening (25 to 60 years) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Other Age Groups (1 to 25 & Above 60 years) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Rapid Point-of-Care Testing for Sickle Cell Anemia: Sector Type movement analysis
  • Fig. 39 Rapid Point-of-Care Testing for Sickle Cell Anemia: Sector Type outlook and key takeaways
  • Fig. 40 Government Labs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Private Labs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Corporate Labs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 PPP (Public-Private-Partnerships) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Rapid Point-of-Care Testing for Sickle Cell Anemia: End use movement analysis
  • Fig. 45 Rapid Point-of-Care Testing for Sickle Cell Anemia: End use outlook and key takeaways
  • Fig. 46 Hospitals & Clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Diagnostics Laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Research Institutions market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Homecare Settings market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Rapid Point-of-Care Testing for Sickle Cell Anemia: Distribution movement analysis
  • Fig. 52 Rapid Point-of-Care Testing for Sickle Cell Anemia: Distribution Channel outlook and key takeaways
  • Fig. 53 B2B (Business-to-Business) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 B2C (Business-to-Consumer) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Global rapid point-of-care testing for sickle cell anemia market: Regional movement analysis
  • Fig. 56 Global rapid point-of-care testing for sickle cell anemia market: Regional outlook and key takeaways
  • Fig. 57 Global rapid point-of-care testing for sickle cell anemia market shares and leading players
  • Fig. 58 North America
  • Fig. 59 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 U.S.
  • Fig. 61 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Canada
  • Fig. 63 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Mexico
  • Fig. 65 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Europe
  • Fig. 67 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 UK
  • Fig. 69 UK market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Germany
  • Fig. 71 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 France
  • Fig. 73 France market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Italy
  • Fig. 75 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Spain
  • Fig. 77 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Denmark
  • Fig. 79 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Sweden
  • Fig. 81 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Norway
  • Fig. 83 Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Asia Pacific
  • Fig. 85 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 China
  • Fig. 87 China market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Japan
  • Fig. 89 Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 90 India
  • Fig. 91 India market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 Thailand
  • Fig. 93 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 94 South Korea
  • Fig. 95 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 96 Australia
  • Fig. 97 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 98 Latin America
  • Fig. 99 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 100 Brazil
  • Fig. 101 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 102 Argentina
  • Fig. 103 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 104 Middle East and Africa
  • Fig. 105 Middle East and Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 106 South Africa
  • Fig. 107 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 108 Saudi Arabia
  • Fig. 109 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 110 UAE
  • Fig. 111 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 112 Kuwait
  • Fig. 113 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 114 Market share of key market players- Rapid Point-of-Care Testing for Sickle Cell Anemia